Clinical trial NCT03037840: Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients
Official title: Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients In Vivo
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neoplasms
Keywords: RF EMF
In Vivo
tumor specific frequencies
Lead sponsor: Southern Medical University, China
Sponsor class: OTHER
Collaborators: name: Nanfang Hospital, Southern Medical University
name: Guangdong 999 Brain Hospital
name: The 157th Hospital of PLA,China
First posted: 2017-01-31
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. The patients who are diagnosed with cancer disease
2. Healthy participators

Brief summary: Studies have shown that tumor specific amplitude-modulated frequencies of radiofrequency electromagnetic fields that is associated with biofeedback upon exposure to in cancer patients. However, such discovery in other cancer patients are rare. And whether tumor specific frequencies can be found in Asian cancer patients remains unclear. The purpose of this study is to detect the tumor specific frequencies of Asian cancer patients in vivo.

Detailed description: The measurements were safety guaranteed and were conducted in hospital. Before detecting, the patient will be already diagnosed with cancer. The doctor and the operator are responsible for the detecting. When cancer patients are exposure to the RF electromagnetic fields, the radial pulse amplitude, blood pressure, skin electrical resistance and breath will be monitored. Biofeedback parameters will be recorded at different modulation frequencies and analyzed in order to find the variation and tumor specific frequencies.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of cancer Disease

Exclusion Criteria:

* other patients

Primary outcomes:
measure: Biofeedback response of cancer patients at the exposure of Low intensity amplitude-modulated radiofrequency electromagnetic fields
timeFrame: within 20 min of exposure
Secondary outcomes:
measure: Representation of autonomous response during the exposure of tumor specific frequencies modutated RF eletromagnetic fields
timeFrame: within 20 min of exposure
Other outcomes:
Locations:
Study officials:
affiliation: School of Biomedical Engineering,Southern Medical University
name: Xin Sherman Xuegang, professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Guangdong 999 Brain Hospital
name: Cai Linbo, master
role: STUDY_DIRECTOR
affiliation: Nanfang Hospital, Southern Medical University
name: Zhu Xiaoxia, PhD
role: STUDY_DIRECTOR
affiliation: The 157th Hospital of PLA
name: Liu Xiantang, bachelor
role: STUDY_DIRECTOR
References:
citation: Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, Kuster N, Pasche B. Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res. 2009 Apr 14;28(1):51. doi: 10.1186/1756-9966-28-51.
citation: Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23;105(5):640-8. doi: 10.1038/bjc.2011.292. Epub 2011 Aug 9.
citation: Zimmerman JW, Pennison MJ, Brezovich I, Yi N, Yang CT, Ramaker R, Absher D, Myers RM, Kuster N, Costa FP, Barbault A, Pasche B. Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer. 2012 Jan 17;106(2):307-13. doi: 10.1038/bjc.2011.523. Epub 2011 Dec 1.
citation: Zimmerman JW, Jimenez H, Pennison MJ, Brezovich I, Morgan D, Mudry A, Costa FP, Barbault A, Pasche B. Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer. 2013 Nov;32(11):573-81. doi: 10.5732/cjc.013.10177.